Role Of MMP-2 and MMP-9 in Resistance to Drug Therapy in Patients with Resistant Hypertension

Background Despite the increased evidence of the important role of matrix metalloproteinases (MMP-9 and MMP‑2) in the pathophysiology of hypertension, the profile of these molecules in resistant hypertension (RHTN) remains unknown. Objectives To compare the plasma levels of MMP-9 and MMP-2 and of their tissue inhibitors (TIMP-1 and TIMP-2, respectively), as well as their MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios, between patients with controlled RHTN (CRHTN, n=41) and uncontrolled RHTN (UCRHTN, n=35). In addition, the association of those parameters with clinical characteristics, office blood pressure (BP) and arterial stiffness (determined by pulse wave velocity) was evaluate in those subgroups. Methods This study included 76 individuals diagnosed with RHTN and submitted to physical examination, electrocardiogram, and laboratory tests to assess biochemical parameters. Results Similar values of MMP-9, MMP-2, TIMP-1, TIMP-2, and MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios were found in the UCRHTN and CRHTN subgroups (P>0.05). A significant correlation was found between diastolic BP (DBP) and MMP-9/TIMP-1 ratio (r=0.37; P=0.02) and DPB and MMP-2 (r=-0.40; P=0.02) in the UCRHTN subgroup. On the other hand, no correlation was observed in the CRHTN subgroup. Logistic regression models demonstrated that MMP-9, MMP-2, TIMP-1, TIMP-2 and their ratios were not associated with the lack of BP control. Conclusion These findings suggest that neither MMP-2 nor MMP-9 affect BP control in RHTN subjects.

• Publication year

  2015

• Venue

  Arquivos Brasileiros de Cardiologia

• Publication date

  2015-06-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.5935/abc.20150060PMID 26039662PMCID 4559126
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Deregulation of adipokines related to target organ damage on resistant hypertension

  2014cited by this paper
• High-circulating leptin levels are associated with increased blood pressure in uncontrolled resistant hypertension

  2013cited by this paper
• Hypoadiponectinemia and aldosterone excess are associated with lack of blood pressure control in subjects with resistant hypertension

  2013cited by this paper
• Circulating matrix metalloproteinases and their inhibitors in hypertension.

  2012cited by this paper
• Vascular stiffness and endothelial dysfunction: Correlations at different levels of blood pressure

  2012cited by this paper
• Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness

  2011cited by this paper
• Consistent alterations of circulating matrix metalloproteinases levels in untreated hypertensives and in spontaneously hypertensive rats: a relevant pharmacological target.

  2011cited by this paper
• Biomarkers of Extracellular Matrix Metabolism (MMP-9 and TIMP-1) and Risk of Stroke, Myocardial Infarction, and Cause-Specific Mortality: Cohort Study

  2011cited by this paper
• Effect of angiotensin-converting enzyme inhibitor on matrix metalloproteinase-9 activity in patients with Kawasaki disease.

  2010cited by this paper
• Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling.

  2010cited by this paper
• Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment.

  2009cited by this paper
• Relations of Matrix Remodeling Biomarkers to Blood Pressure Progression and Incidence of Hypertension in the Community

  2009cited by this paper
• Progress in matrix metalloproteinase research.

  2008cited by this paper
• Primary Aldosteronism in Diabetic Subjects With Resistant Hypertension

  2008cited by this paper
• Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

  2008cited by this paper
• Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

  2008cited by this paper
• Increased Matrix Metalloproteinase 2 Activity in the Human Internal Mammary Artery Is Associated with Ageing, Hypertension, Diabetes and Kidney Dysfunction

  2008cited by this paper
• Aldosterone and the Vasculature: Mechanisms Mediating Resistant Hypertension

  2007cited by this paper
• Aortic pulse wave velocity: an independent marker of cardiovascular risk.

  2007cited by this paper
• Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature

  2007cited by this paper
• Impact of the Metalloproteinase-9/Tissue Inhibitor of Metalloproteinase-1 System on Large Arterial Stiffness in Patients with Essential Hypertension

  2007cited by this paper
• Matrix metalloproteinase-9 polymorphism contributes to blood pressure and arterial stiffness in essential hypertension

  2007cited by this paper
• Expert consensus document on arterial stiffness: methodological issues and clinical applications.

  2006cited by this paper
• Structure and function of matrix metalloproteinases and TIMPs.

  2006cited by this paper
• Matrix Metalloproteinases/Tissue Inhibitors of Metalloproteinases: Relationship Between Changes in Proteolytic Determinants of Matrix Composition and Structural, Functional, and Clinical Manifestations of Hypertensive Heart Disease

  2006cited by this paper
• Vascular remodeling and protease inhibition--bench to bedside.

  2006cited by this paper
• Diagnosis of primary aldosteronism: from screening to subtype differentiation.

  2005cited by this paper
• Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension.

  2005cited by this paper
• Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension Relationship to tissue Doppler indices of diastolic relaxation.

  2004cited by this paper
• Pressure-Induced Matrix Metalloproteinase-9 Contributes to Early Hypertensive Remodeling

  2004cited by this paper
• Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.

  2004cited by this paper
• Low-renin status in therapy-resistant hypertension: a clue to efficient treatment

  2004cited by this paper
• Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region

  2003cited by this paper
• Hyperaldosteronism Among Black and White Subjects With Resistant Hypertension

  2002cited by this paper
• Increased expression of matrix metalloproteinase-2: a diagnostic marker but not prognostic marker of papillary thyroid carcinoma.

  2002cited by this paper
• TIMP-1: A Marker of Left Ventricular Diastolic Dysfunction and Fibrosis in Hypertension

  2002cited by this paper
• Aortic Stiffness Is an Independent Predictor of All-Cause and Cardiovascular Mortality in Hypertensive Patients

  2001cited by this paper
• Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor.

  1999cited by this paper
• Enhanced expression of tissue inhibitor of metalloproteinase‐2 (TIMP‐2) in the stroma of breast carcinomas correlates with tumor recurrence

  1994cited by this paper
• Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases.

  1993cited by this paper

• Activity of matrix metalloproteinase type 9 and its relationship with calcification of the thoracic aorta in patients with resistant hypertension: cross-sectional comparative study

  2023cites this paper
• Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions

  2023cites this paper
• Machine Learning Application Identifies Germline Markers of Hypertension in Patients With Ovarian Cancer Treated With Carboplatin, Taxane, and Bevacizumab

  2023cites this paper
• Matrix metaloproteinases in vascular pathology.

  2022cites this paper
• Polygonum cuspidatum glycoside mitigated LPS-induced human endometrial stromal cell inflammation by regulating NF-κB/Nrf2 signaling pathway-related proteins

  2022cites this paper
• Identification of Aortic Proteins Involved in Arterial Stiffness in Spontaneously Hypertensive Rats Treated With Perindopril:A Proteomic Approach

  2021cites this paper
• Brazilian Position Statement on Resistant Hypertension – 2020

  2020cites this paper
• Posicionamento Brasileiro sobre Hipertensão Arterial Resistente – 2020

  2020cites this paper
• Prediction of the early response to spironolactone in resistant hypertension by the combination of matrix metalloproteinase-9 activity and arterial stiffness parameters.

  2020cites this paper
• RESISTANT ARTERIAL HYPERTENSION

  2018cites this paper
• Controlled Versus Uncontrolled Resistant Hypertension: Are They in the Same Bag?

  2018cites this paper
• Matrix Metalloproteinase-9 (MMP-9) Level in Tuberculosis Exposed and Infected Children

  2017cites this paper